INCY - Incyte and Cellenkos inks global pact for development for CK0804 in MF patients

Incyte Corporation ([[INCY]] +2.6%) and Cellenkos inks a development collaboration to evaluate the combination of Jakafi (ruxolitinib) and CK0804, Cellenkos' cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis, MF.Additionally, Incyte has an exclusive option to acquire sole rights to develop and commercialize CK0804, and genetically-modified variants of CK0804, in benign and malignant hematology indications.Under the terms of the agreement, the companies plan to initiate a Phase 1b single arm, open-label study evaluating ruxolitinib in combination with CK0804 in patients with MF. As per collaboration, Cellenkos will be eligible to receive a $20M licensing fee and sales milestones totaling up to $294.5M as well as tiered royalties ranging from mid-single digit to low-double digits, if approved.Incyte will fund the study and will be operationalized by Cellenkos.

For further details see:

Incyte and Cellenkos inks global pact for development for CK0804 in MF patients